Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price was down 1.2% during trading on Tuesday . The stock traded as low as $3.40 and last traded at $3.43, with a volume of 153,446 shares trading hands. The stock had previously closed at $3.47.

Several equities analysts have commented on RGLS shares. Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Tuesday, May 3rd. Wells Fargo & Co. began coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. They issued a “buy” rating on the stock. Cowen and Company restated a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. BMO Capital Markets restated a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Finally, Zacks Investment Research downgraded shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $10.17.

The stock’s market capitalization is $181.70 million. The company has a 50-day moving average of $3.52 and a 200 day moving average of $5.51.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. Equities analysts predict that Regulus Therapeutics Inc. will post ($1.59) EPS for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.